Aquestive Therapeutics

📍 Warren, United States👥 145 employees💰 Last funded Aug 2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
Founded
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Aquestive Therapeutics?
Aquestive Therapeutics has 1 investors on record on gritt.io.
When did Aquestive Therapeutics last raise funding?
The most recent investment in Aquestive Therapeutics recorded on gritt.io was in August 2022.
What industry is Aquestive Therapeutics in?
Aquestive Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Aquestive Therapeutics based?
Aquestive Therapeutics is headquartered in Warren, United States.